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Since the World Health Organization (WHO) launched the Global Antimicrobial Resistance 
Surveillance System (GLASS) in 2015,1 there has been rapidly growing awareness among many 
African countries that they need to be doing more to combat antimicrobial resistance (AMR). The 
Africa Centres for Disease Control and Prevention (CDC) was officially inaugurated in January 
20172 and will support countries commencing surveillance for serious infectious disease threats 
in Africa, including resistance. Review of the recent WHO GLASS report suggests that, while 
certain nations do have some surveillance systems in place, very few countries in Africa currently 
conduct effective routine surveillance.1 As editors of this special edition, our experience confirms 
this observation. Nonetheless, we were encouraged by the range and scope of articles we received 
when the call for this special edition went out. The subjects covered include multi-drug resistant 
tuberculosis,3,4,5 which remains a critical public health threat on the African continent, nosocomial 
infections,6,7 including those due to Clostridium difficile8, laboratory methods and technical 
issues,9,10 including external quality assessment11 and molecular methods,3,12,13 and malaria.14 
Community-acquired resistance was underrepresented, although there was a major review on 
AMR in Vibrio cholerae O1.15 The articles included opinion pieces, general and systematic reviews 
and original research. What we missed was more original research with a wider range of country 
submissions and better regional representation, more articles looking at One Health, veterinary 
medicine and AMR, more studies with data on AMR in community-acquired pathogens and 
AMR trend data by country, including bacteria, fungi and parasitic infections, and better detail 
on antiretroviral resistance in HIV infection. We are pleased to find that the special issue’s Call 
for Papers increased the overall frequency of submissions in this area and so subsequent regular 
issues of the journal are likely to continue the exposition of AMR surveillance in Africa that this 
issue has initiated.
Omissions notwithstanding, what is represented in this issue is a great and promising start: 
GLASS and the Africa CDC are both still in their infancy and no country can be expected to begin 
with comprehensive surveillance. What we have seen and present in this issue is an architect’s 
rough sketch of where we can go as a continent. Readers should understand that surveillance for 
AMR, irrespective of the pathogen or the setting, is not about the academic exercise of data 
collection but is a practical and powerful tool that is critical in defining optimal interventions both 
in local health settings and for what has become a global health crisis.
When AMR surveillance data are published in a journal, compared with submitting national data 
to a supra-governmental organisation, these data need not be fully comprehensive or subscribe to 
a predetermined list of pathogens or antimicrobials. The articles in this special edition hence 
provide a valuable snapshot of what can be done in Africa, rather than a comprehensive analysis 
of the AMR surveillance in Africa. Readers of this special edition, which emphasised the need for 
planning and progress as well as AMR data, should be able to see beyond the AMR data published 
here to what is being achieved by their continental neighbours, recognising that they too have the 
potential to do similar work. Remembering that imitation is the highest form of flattery, we can 
use the experience of our neighbours, start small and grow our surveillance systems. There are 
new resources that we can access through the WHO1 and Africa CDC2,16 to support us. The 
responsibility rests with us to find the will and the way to take surveillance for AMR to the next 
phase of effective implementation.
We all concede that there are numerous challenges we face in our attempt to implement effective 
and sustainable AMR surveillance programmes in Africa. These challenges range from inadequate 
resources and weak supply chains for consumables for microbiological laboratory procedures, lack 
of human resources well trained in AMR surveillance and poor or lack of commitment by facility 
management to embrace AMR as a healthcare issue. Where facilities do exist, under-utilisation is 
common. However, despite the lack of infrastructure and other resources required to perform 
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optimal surveillance for AMR, most laboratories in Africa can 
still generate, collate and disseminate quality data, albeit with 
some ingenuity. If there is a lack of samples for systematic 
evaluation of AMR trends, mutually beneficial partnerships 
between centres responsible for coordinating surveillance and 
local hospitals or healthcare facilities can jumpstart focused 
surveillance on specific organisms. Such centres can then 
gradually expand the surveillance to include more pathogens 
and more facilities. Indeed, we could perform systematic 
sentinel surveillance so as to generate reliable, accurate and 
quality-controlled data, using the minimal resources typically 
available in our settings, for implementation of infection 
control and prevention programmes. Similarly, livestock-
serving veterinary laboratories could target a component of 
the meat value chain and purposively sample within their 
capacity, for example, one in every 10 meat swabs in the local 
abattoir for AMR testing and surveillance. This effort can 
additionally be embedded in the public health requirement 
for ensuring food safety. Quality routine culture and 
susceptibility testing can easily and cost-effectively provide 
high-quality surveillance data. However, as Omar et al.,3 
Smith,12 Gellband13 and Mohammed et al.15 all demonstrate, 
additional valuable information can be gleaned from 
surveillance systems that use whole genome sequencing and 
this is something that developing systems should consider. 
For quality assurance, which is a hallmark of a standard 
surveillance system, it will be important for laboratories to 
be registered and participate in an external quality 
assessment scheme operating to internationally recognised 
standards, some of which are supported by WHO and other 
partners and are therefore potentially more affordable for 
laboratories in our African setting.
Implementation of national action plans for AMR surveillance 
from a One Health approach will be critical in ensuring 
sustainability of the collaborative, multi-sectoral, and trans-
disciplinary efforts at the local, regional and national level. 
Leveraging resources that can be jointly deployed both 
in-country and across national borders for sample collection, 
laboratory analysis, and data capture, analysis and 
dissemination, will optimise the use of resources to achieve 
the desired goals, providing evidence for action to prevent 
and contain AMR. On funding AMR surveillance activities 
and for a sustainable AMR surveillance programme, it will 
be critical that budget commitments made by national 
governments to support the national action plan activities are 
adequately maintained. This too will require some ingenuity 
so as to demonstrate that data from AMR surveillance 
actually impact on delivery of healthcare, food security and 
sustenance of a healthy environment. Thus, governments are 
constantly reminded that good surveillance systems are 
actually cost efficient, particularly in the long term. We need 
to work with health economists to deliver data on those 
economic costs associated with a lack of action on the 
AMR menace in our countries in a language that policymakers 
will easily understand. In the meantime, we will need to 
utilise the resources currently available through various 
initiatives, such as the tripartite United Nations agencies 
(WHO, the Food and Agriculture Organization and the 
World Organization for Animal Health), as well as other 
partners who have specific interests in promoting and 
supporting One Health AMR surveillance in Africa. The 
outlines of two successful routes to national surveillance, 
Ibrahim et al.17 and Opintan18, showcase how donor funds 
were leveraged to support local planning and initiatives in 
Ethiopia and Ghana. In making the most of external initiatives 
and opportunities, however, we must remember that these 
will only serve as short- and medium-term solutions – we 
have to own the process of fully implementing our national 
action plans, using our own resources, if AMR surveillance 
and containment will be sustainable, and serve our principal 
national goals and objectives. 
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